Valentina Svicher

University of Rome Tor Vergata — Italy

Medicine · Health Sciences

34h-index3.4kcitations270works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis B Virus Studies(146), Hepatitis C virus research(141), HIV Research and Treatment(90), Liver Disease Diagnosis and Treatment(77), HIV/AIDS drug development and treatment(76)

Publications269 total

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program
Journal of Hepatology·2025
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
Journal of Antimicrobial Chemotherapy·2025· 1 citedOpen Access
Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study
Journal of Clinical Virology·2025· 3 citedOpen Access
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
Journal of Antimicrobial Chemotherapy·2025· 5 citedOpen Access
OC48 HBV integration can sustain intrahepatic HDV activity and can modulate HBV pathogenetic potential
2025
OC24 An increased genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity
2025
P76 The substantial burden of HDV chronic infection and the gaps in HDV screening across Europe rise the need to implement HDV diagnostics at pan-European level
Poster·2025
P72 Experience from a single centre on HBV seroconversion in people living with HIV and HBV: the relevance of individual clinical history and careful monitoring of viral markers
Poster·2025
SC25 Comparable dynamics of cell-associated HIV-RNA, total and intact proviral HIV-1 DNA in virologically suppressed people with HIV switching to 2DR or continuing 3DR over a 18-month follow-up
2025
SC15 Clinical and laboratory parameters correlated to HDV undetectability after 48 weeks of bulevirtide
2025
Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles
Viruses·2025· 3 citedOpen Access
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy
Journal of Antimicrobial Chemotherapy·2025· 1 citedOpen Access
OS-072-YI HBV integration can sustain HDV persistence especially in the setting of an absent HBV reservoir and can be a biomarker of response to bulevirtide
Journal of Hepatology·2025
SAT-316 Sustained HBsAg loss in HIV/HBV-coinfected patients is not a rare event under HBV-active ART even if a residual risk of viral reactivation and liver disease progression still persists over time
Journal of Hepatology·2025
OS-015 The burden of HDV chronic infection and the gaps in HDV screening across Europe: an urgent need to strengthen diagnostic strategies at pan-european level
Journal of Hepatology·2025· 1 cited
<scp>HBsAg</scp> Isoforms as Innovative Biomarkers in Predicting Virological Response to Bulevirtide in Patients With Chronic Hepatitis D
Liver International·2025· 2 cited
Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against Respiratory Syncytial Virus
2025Open Access
Comparison of diagnostic performances of HDV RNA quantification assays used in clinical practice in Italy: data from the first national quality control multicenter study
Digestive and Liver Disease·2025· 1 cited
HDV persistence acts independently from HBV reservoir extent and is sustained by HBsAg production mainly derived from integrated HBV-DNA
Digestive and Liver Disease·2025· 1 cited
The transactivation of human endogenous retroviruses is associated with HIV-1 reservoir, lymphocyte activation and low CD4 count in virologically suppressed PLWH
Microbes and Infection·2025· 1 citedOpen Access
page 1 of 14Next →

Frequent Co-authors

Carlo Federico Perno(44), Francesca Ceccherini‐Silberstein(30), Romina Salpini(20), Massimo Andreoni(15), Claudia Alteri(14), Ada Bertoli(14), Andrea Antinori(14), Maria Mercedes Santoro(11), Valeria Micheli(11), Caterina Gori(11), Roberta D’Arrigo(11), M. Angélico(9), Anna Artese(9), Stefano Alcaro(9), Michela Pollicita(8), Valeria Cento(8), Antonella d’Arminio Monforte(8), Stefano Aquaro(8), C. Sarrecchia(7), Loredana Sarmati(7)